A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Inclusion criteria

• Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
• Patients with histologically or cytologically confirmed unresectable solid tumors;
• At least one measurable lesion was identified per RECIST 1.1;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
• Adequate organ functions as defined per protocol;
• Minimum life expectancy of 3 months.

Exclusion criteria

• Patients with known active central nervous system (CNS) metastases;
• History of other malignancy within the past 5 years, with exceptions defined in the protocol;
• Patients with uncontrolled cancer pain;
• Patients with serious cardiovascular and/or cerebrovascular diseases;
• Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
• Patients with Severe infections within 4 weeks prior to the first dose;
• Active pulmonary tuberculosis infection;
• History of immunodeficiency;
• History of autoimmune diseases;
• The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;
• Pregnant or nursing women, or planned to become pregnant during the study period;
• Known allergic to any component of investigational drugs.